Assessing the introduction of universal rotavirus vaccination in the Netherlands

T. P. Zomer; Y. T. H. P. van Duynhoven; M. J. J. Mangen; N. A. T. van der Maas; H. Vennema; H. Boot; H. E. de Melker

doi:10.1016/j.vaccine.2008.04.039

Assessing the introduction of universal rotavirus vaccination in the Netherlands

T. P. Zomer
, Y. T. H. P. van Duynhoven
, M. J. J. Mangen
, N. A. T. van der Maas
, H. Vennema
, H. Boot
, H. E. de Melker^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

Rotarix and RotaTeq are both prophylactic vaccines against rotavirus (RV) gastroenteritis. In 2006, these vaccines obtained a European license and because RV infections are widespread among Dutch children inclusion of these vaccines in the Dutch National Immunization Program(NIP) should be considered. Using an evaluation model for introducing a new vaccine, we assessed the introduction of universal RV vaccination in the Netherlands. Although post-marketing surveillance will be essential, both RV vaccines have proven to be safe and effective. Furthermore, the vaccines will prevent most of the RV-related hospitalizations and deaths. However, for the Netherlands with the current vaccine prices, universal RV vaccination is not expected to be cost-effective. (C) 2008 Elsevier Ltd. All rights reserved.

Original language	English
Pages (from-to)	3757-3764
Number of pages	8
Journal	Vaccine
Volume	26
Issue number	29-30
DOIs	https://doi.org/10.1016/j.vaccine.2008.04.039
Publication status	Published - 4 Jul 2008

Keywords

rotavirus vaccination
gastroenteritis
National Immunization Program
cost-effectiveness
GROUP-A ROTAVIRUS
RISK-FACTORS
UNITED-STATES
VIRAL GASTROENTERITIS
CEREBROSPINAL-FLUID
MALAWIAN CHILDREN
HEALTHY INFANTS
INFECTION
SAFETY
EFFICACY

Access to Document

10.1016/j.vaccine.2008.04.039

Cite this

@article{f95376ec36b94545a221e2957933427f,

title = "Assessing the introduction of universal rotavirus vaccination in the Netherlands",

abstract = "Rotarix and RotaTeq are both prophylactic vaccines against rotavirus (RV) gastroenteritis. In 2006, these vaccines obtained a European license and because RV infections are widespread among Dutch children inclusion of these vaccines in the Dutch National Immunization Program(NIP) should be considered. Using an evaluation model for introducing a new vaccine, we assessed the introduction of universal RV vaccination in the Netherlands. Although post-marketing surveillance will be essential, both RV vaccines have proven to be safe and effective. Furthermore, the vaccines will prevent most of the RV-related hospitalizations and deaths. However, for the Netherlands with the current vaccine prices, universal RV vaccination is not expected to be cost-effective. (C) 2008 Elsevier Ltd. All rights reserved.",

keywords = "rotavirus vaccination, gastroenteritis, National Immunization Program, cost-effectiveness, GROUP-A ROTAVIRUS, RISK-FACTORS, UNITED-STATES, VIRAL GASTROENTERITIS, CEREBROSPINAL-FLUID, MALAWIAN CHILDREN, HEALTHY INFANTS, INFECTION, SAFETY, EFFICACY",

author = "Zomer, \{T. P.\} and \{van Duynhoven\}, \{Y. T. H. P.\} and Mangen, \{M. J. J.\} and \{van der Maas\}, \{N. A. T.\} and H. Vennema and H. Boot and \{de Melker\}, \{H. E.\}",

year = "2008",

month = jul,

day = "4",

doi = "10.1016/j.vaccine.2008.04.039",

language = "English",

volume = "26",

pages = "3757--3764",

journal = "Vaccine",

issn = "0264-410X",

publisher = "Elsevier Limited",

number = "29-30",

}

TY - JOUR

T1 - Assessing the introduction of universal rotavirus vaccination in the Netherlands

AU - Zomer, T. P.

AU - van Duynhoven, Y. T. H. P.

AU - Mangen, M. J. J.

AU - van der Maas, N. A. T.

AU - Vennema, H.

AU - Boot, H.

AU - de Melker, H. E.

PY - 2008/7/4

Y1 - 2008/7/4

N2 - Rotarix and RotaTeq are both prophylactic vaccines against rotavirus (RV) gastroenteritis. In 2006, these vaccines obtained a European license and because RV infections are widespread among Dutch children inclusion of these vaccines in the Dutch National Immunization Program(NIP) should be considered. Using an evaluation model for introducing a new vaccine, we assessed the introduction of universal RV vaccination in the Netherlands. Although post-marketing surveillance will be essential, both RV vaccines have proven to be safe and effective. Furthermore, the vaccines will prevent most of the RV-related hospitalizations and deaths. However, for the Netherlands with the current vaccine prices, universal RV vaccination is not expected to be cost-effective. (C) 2008 Elsevier Ltd. All rights reserved.

AB - Rotarix and RotaTeq are both prophylactic vaccines against rotavirus (RV) gastroenteritis. In 2006, these vaccines obtained a European license and because RV infections are widespread among Dutch children inclusion of these vaccines in the Dutch National Immunization Program(NIP) should be considered. Using an evaluation model for introducing a new vaccine, we assessed the introduction of universal RV vaccination in the Netherlands. Although post-marketing surveillance will be essential, both RV vaccines have proven to be safe and effective. Furthermore, the vaccines will prevent most of the RV-related hospitalizations and deaths. However, for the Netherlands with the current vaccine prices, universal RV vaccination is not expected to be cost-effective. (C) 2008 Elsevier Ltd. All rights reserved.

KW - rotavirus vaccination

KW - gastroenteritis

KW - National Immunization Program

KW - cost-effectiveness

KW - GROUP-A ROTAVIRUS

KW - RISK-FACTORS

KW - UNITED-STATES

KW - VIRAL GASTROENTERITIS

KW - CEREBROSPINAL-FLUID

KW - MALAWIAN CHILDREN

KW - HEALTHY INFANTS

KW - INFECTION

KW - SAFETY

KW - EFFICACY

U2 - 10.1016/j.vaccine.2008.04.039

DO - 10.1016/j.vaccine.2008.04.039

M3 - Article

C2 - 18514975

SN - 0264-410X

VL - 26

SP - 3757

EP - 3764

JO - Vaccine

JF - Vaccine

IS - 29-30

ER -

Assessing the introduction of universal rotavirus vaccination in the Netherlands

Abstract

Keywords

Access to Document

Fingerprint

Cite this